Antag is testing AT7687, a GIP receptor antagonist, combined with semaglutide in a Phase 2a trial for weight loss and type 2 diabetes management. The 13-week study enrolls 150 participants to evaluate body weight reduction and glycemic control as primary and secondary endpoints, with results expected in H1 2027.
Key Points
- GIP receptor antagonism combined with semaglutide targets dual metabolic pathways
- Phase 1 showed favorable safety profile with no serious adverse events
- Primary outcome measures body weight; secondary measures HbA1c and cardiometabolic markers
Longevity Analysis
Dual-mechanism pharmacology targeting GIP receptors alongside GLP-1 pathways represents a shift in metabolic disease intervention—addressing both energy regulation and glucose homeostasis simultaneously. For individuals with concurrent obesity and type 2 diabetes, this approach may reduce the metabolic dysfunction underlying accelerated aging and cardiovascular disease. The focus on cardiometabolic biomarkers in exploratory measures suggests recognition that weight reduction alone is insufficient; the goal is restoring metabolic resilience and reducing systemic inflammation that drives age-related disease.
Original published by LT Wire.